Impaired response to first SARS‐CoV ‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

(2021) Tiziano Barbui et al.   LEUKEMIA

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

(2021) Tiziano Barbui et al.   Blood Cancer Journal

Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity

(2021) L. Vanderbeke et al.   Nature Communications

Long-term follow-up of recovered MPN patients with COVID-19

(2021) Tiziano Barbui et al.   Blood Cancer Journal

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

(2020) F. La Rosée et al.   LEUKEMIA

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

(2020) Francesco Passamonti et al.   Lancet Haematology

Cell‐mediated and humoral adaptive immune responses to SARS‐CoV‐2 are lower in asymptomatic than symptomatic COVID‐19 patients

(2020) Alessio Mazzoni et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

(2020) Alessandro M. Vannucchi et al.   LEUKEMIA

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

(2020) Abi Vijenthira et al.   BLOOD

The safety of JAK kinase inhibitors for the treatment of myelofibrosis

(2020) Giacomo Coltro et al.   Expert Opinion On Drug Safety

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

(2015) R Zeiser et al.   LEUKEMIA

Immunological Consequences of JAK Inhibition: Friend or Foe?

(2015) Donal P. McLornan et al.   Current Hematologic Malignancy Reports

Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis

(2011) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS